financetom
Business
financetom
/
Business
/
Tyson Foods beats quarterly profit estimates even as sales slip
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Tyson Foods beats quarterly profit estimates even as sales slip
May 6, 2024 4:53 AM

May 6 (Reuters) - Tyson Foods ( TSN ) surpassed Wall

Street expectations for second-quarter profit on Monday, as it

begins to reap the benefits of shutting some chicken processing

plants to reduce costs.

The biggest U.S. meat company by sales has shuttered six

U.S. chicken plants since the start of last year, laid off

corporate employees and announced plans to close a pork plant,

in an attempt to rein in costs.

That helped it post adjusted earnings of 62 cents per share

for the second quarter, compared with analysts' average estimate

of 39 cents, based on LSEG data.

However, it has been grappling with slowing demand over the

last few quarters as price-conscious customers cut back on

expensive purchases and look for affordable options amid

still-high food prices and borrowing costs.

Tyson's second-quarter net sales fell 0.5% to $13.07

billion, compared with estimates of $13.16 billion.

Sales in the chicken segment, which struggled with excess

supply during 2023, were down 8.3% in the quarter even though

prices fell 2.1%. Volumes dropped by 6.1%.

On the other hand, volumes at the beef segment - its largest

- grew for the first time in five quarters, logging a 2.8%

increase. The company's pork segment also saw volumes increase

by 2.9%.

In the quarter, the operating margin in Tyson's beef

business dropped by 0.7%. The business has grappled with limited

U.S. cattle supplies since last year.

Tyson, the maker of Ball Park hotdogs, said it continues to

expect total sales to be flat in fiscal 2024, compared with the

previous year's $52.88 billion.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Gain Therapeutics Says Australia Approves Start of Phase 1b Parkinson's Disease Study
Gain Therapeutics Says Australia Approves Start of Phase 1b Parkinson's Disease Study
Dec 23, 2024
09:00 AM EST, 12/23/2024 (MT Newswires) -- Gain Therapeutics ( GANX ) said Monday it has received approval in Australia to start a phase 1b trial of GT-02287, the company's lead allosteric small molecule in clinical development to treat Parkinson's disease with or without a GBA1 mutation. The main objective of the phase 1b trial is to evaluate the safety...
Agnico Acquires 15% Stake in ONGold Resources, Participates in White Gold Financing
Agnico Acquires 15% Stake in ONGold Resources, Participates in White Gold Financing
Dec 23, 2024
09:02 AM EST, 12/23/2024 (MT Newswires) -- Agnico Eagle Mines ( AEM ) said Monday it has acquired 8.7 million shares of ONGold Resources ( ONGRF ) , which translates to 15% of the company on a non-diluted basis. The two companies signed an investor rights agreement, with ONGold granting Agnico Eagle certain rights to maintain its pro rata ownership...
CIBC Comments on Canada's GDP Data
CIBC Comments on Canada's GDP Data
Dec 23, 2024
09:00 AM EST, 12/23/2024 (MT Newswires) -- The Canadian economy appears to have been on a stronger footing than initially expected entering Q4, although early evidence for November suggests momentum has waned again, said CIBC. October's gross domestic product posted a healthy 0.3% month-over-month advance, which was a tick above the consensus and two ticks better than the early estimate...
Tonix Pharmaceuticals Says FDA Set Target Action Date for Potential Fibromyalgia Drug
Tonix Pharmaceuticals Says FDA Set Target Action Date for Potential Fibromyalgia Drug
Dec 23, 2024
08:59 AM EST, 12/23/2024 (MT Newswires) -- Tonix Pharmaceuticals ( TNXP ) said Monday that the US Food and Drug Administration had set a target action date of Aug. 15, 2025, for TNX-102 SL sublingual tablets to potentially treat fibromyalgia. The company said its new drug application for TNX-102 SL, or cyclobenzaprine HCl, is supported by the results of two...
Copyright 2023-2026 - www.financetom.com All Rights Reserved